Health Canada Approves New Novo Nordisk Semaglutide Brand Names
Health Canada has approved new brand names for Novo Nordisk's semaglutide products, marking a strategic regulatory move as the Danish pharmaceutical giant prepares for generic competition in the Canadian market.
New Brand Names Approved
According to regulatory filings, Health Canada has granted approval for additional brand names for semaglutide formulations from Novo Nordisk. The approvals come as the original Ozempic patent protection expired on January 4, 2026, opening the door for generic competition.
While Ozempic remains the primary brand name for semaglutide 0.25mg, 0.5mg, and 1.0mg pre-filled pens, the new approvals provide Novo Nordisk with additional marketing flexibility as nine generic manufacturers prepare to enter the Canadian market.
Regulatory Strategy Amid Generic Competition
The timing of these brand name approvals appears strategic, occurring as Health Canada reviews applications from multiple generic drug manufacturers. The regulator is currently evaluating submissions from companies including Sandoz, Apotex, Teva, and Aspen Pharmacare for generic semaglutide products.
Industry analysts suggest that securing multiple brand names allows pharmaceutical companies to maintain market presence and differentiate their products even after patent expiration. The strategy could help Novo Nordisk compete against upcoming generic alternatives expected to launch this summer.
Generic Applications Under Review
Health Canada's public tracker shows nine active applications for generic semaglutide products currently under regulatory review. The applications cover various strengths and formulations of the medication, with several companies targeting mid-2026 market entry dates.
Canadian patients have been tracking these developments through resources like our generic semaglutide tracker, as generic versions are expected to significantly reduce current pricing of CAD $300-400 monthly for brand-name products.
Market Preparation
The brand name approvals come as major Canadian pharmacy chains prepare for the arrival of generic alternatives. Shoppers Drug Mart, Costco, and other retailers are reportedly updating their systems to accommodate multiple semaglutide formulations from different manufacturers.
Provincial drug plans are also preparing coverage policies for generic alternatives, with several provinces indicating they will prioritize lower-cost generic options once available. Patients can check potential coverage through our insurance coverage checker.
Competitive Landscape
Beyond semaglutide products, Health Canada continues to review other GLP-1 medications including Eli Lilly's Mounjaro for additional indications. The regulatory body has also approved Wegovy for multiple therapeutic uses, expanding treatment options for Canadian patients.
The approval of new brand names represents one element of the broader competitive dynamics emerging in Canada's GLP-1 medication market, as both brand-name and generic manufacturers position for market share.
Looking Ahead
Health Canada has not disclosed specific details about the new brand names or their intended market positioning. The regulator continues to process generic applications under its 180-day review timeline, with first approvals potentially coming as early as this summer.
For patients seeking current pricing information and updates on generic availability, our FAQ section provides comprehensive guidance on navigating the evolving GLP-1 medication landscape in Canada.
This article is for informational purposes only and does not constitute medical advice.
Get notified when generic prices go live
We’ll send one email the moment generic semaglutide prices are listed at Canadian pharmacies. No spam.
Get notified when generic semaglutide becomes available in Canada
Expected Q3 2026 — be the first to know
